These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacoeconomics under defined contributions and tiered formularies. Lyles A Clin Ther; 2001 Sep; 23(9):1568-9. PubMed ID: 11589268 [No Abstract] [Full Text] [Related]
3. Pharmacoeconomics comes of age? Walley T; Breckenridge A Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057 [TBL] [Abstract][Full Text] [Related]
4. [Bioethics and pharmacoeconomics: a difficult balance]. Felicetti V; Cristina G; Cifaldi L Clin Ter; 2008; 159(1):29-32. PubMed ID: 18399259 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics: integrating economic evaluation into clinical trials. Haycox A; Drummond M; Walley T Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814 [No Abstract] [Full Text] [Related]
6. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? Brinsmead R; Hill S J Clin Pharm Ther; 2003 Aug; 28(4):339-46. PubMed ID: 12911687 [TBL] [Abstract][Full Text] [Related]
7. Comparative experience in home care and pharmaceutical policy. Kane NM; Saltman RB Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467 [No Abstract] [Full Text] [Related]
8. Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing. Bai G; Sen AP; Anderson GF Ann Intern Med; 2018 Mar; 168(6):436-437. PubMed ID: 29435565 [No Abstract] [Full Text] [Related]
9. Pharmaceutical economy and the economic assessment of drugs in France. le Pen C Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787 [TBL] [Abstract][Full Text] [Related]
10. Health economics in primary care in the UK: containment of drug costs. Walley T; Edwards RT Pharmacoeconomics; 1993 Feb; 3(2):100-6. PubMed ID: 10146959 [No Abstract] [Full Text] [Related]
11. [Application of pharmacoeconomics in clinical management]. Amat Díaz M; Poveda Andrés JL; Carrera-Hueso FJ Farm Hosp; 2011 May; 35 Suppl 2():18-24. PubMed ID: 22445505 [TBL] [Abstract][Full Text] [Related]
12. The National Pharmaceuticals Strategy: Rest in peace, revive or renew? MacKinnon NJ; Ip I CMAJ; 2009 Apr; 180(8):801-3. PubMed ID: 19190081 [No Abstract] [Full Text] [Related]
13. Pharmacoeconomics: NICE's approach to decision-making. Rawlins M; Barnett D; Stevens A Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233 [No Abstract] [Full Text] [Related]
14. Initial development of the Australian Guidelines. Freund DA Med Care; 1996 Dec; 34(12 Suppl):DS211-5. PubMed ID: 8969328 [No Abstract] [Full Text] [Related]
15. Current efforts in standards development. United States. Power EJ Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327 [No Abstract] [Full Text] [Related]
16. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
17. A UK national prescribing list? Walley T Pharmacoeconomics; 1995 Jun; 7(6):471-4. PubMed ID: 10155332 [No Abstract] [Full Text] [Related]
18. Current principles and application of pharmacoeconomics. Malek M Pharmacoeconomics; 1996; 9 Suppl 1():1-8. PubMed ID: 10160111 [TBL] [Abstract][Full Text] [Related]
19. Accumulating evidence for the case of differential discounting. Postma MJ; Parouty M; Westra TA Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787 [No Abstract] [Full Text] [Related]
20. Pharmacoeconomics: an emerging discipline. Letizia C Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]